Kausar Fariha, Mustafa Khader, Sweis Ghaleb, Sawaqed Ray, Alawneh Khaldoon, Salloum Rafah, Badaracco Maria, Niewold Timothy B, Sweiss Nadera J
East Chicago Health Center - Internal Medicine, 1313 West Chicago Avenue, East Chicago, Indiana 46312, USA.
Expert Opin Biol Ther. 2009 Jul;9(7):889-95. doi: 10.1517/14712590903018837.
Recent advances in our understanding of B-cell dysregulation and its important link to autoimmunity have brought about a radical change in the management of autoimmune diseases. Over the past few years, encouraging data from several clinical trials of rituximab, a chimeric anti-CD20 antibody, have led to its approval for use in rheumatoid arthritis (RA). These data, regarding clinical efficacy, safety, improved patient-reported outcomes and cost-effectiveness with the use of rituximab in patients with RA, have led to the exploration of other agents targeting B-cell functions. Ocrelizumab, a novel humanized anti-CD20 antibody, has shown clinical efficacy and safety in a recently reported trial in patients with RA. Future clinical trials will help evaluate further the role of ocrelizumab in RA and its potential use in other autoimmune diseases. This review describes current understanding of B-cell therapy, the role of rituximab in the treatment of RA and the evolving role of ocrelizumab as a B-cell-targeted therapy.
我们对B细胞失调及其与自身免疫重要联系的理解取得的最新进展，给自身免疫性疾病的治疗带来了根本性的变革。在过去几年里，嵌合抗CD20抗体利妥昔单抗的多项临床试验得出了令人鼓舞的数据，这使得该药物被批准用于类风湿关节炎（RA）的治疗。这些关于利妥昔单抗在类风湿关节炎患者中使用的临床疗效、安全性、患者报告结局改善以及成本效益的数据，促使人们探索其他靶向B细胞功能的药物。奥瑞珠单抗是一种新型人源化抗CD20抗体，在最近一项针对类风湿关节炎患者的试验中显示出了临床疗效和安全性。未来的临床试验将有助于进一步评估奥瑞珠单抗在类风湿关节炎中的作用及其在其他自身免疫性疾病中的潜在用途。这篇综述描述了目前对B细胞治疗的理解、利妥昔单抗在类风湿关节炎治疗中的作用以及奥瑞珠单抗作为一种靶向B细胞治疗的不断演变的作用。
